Position of the Transparency Council – Chenodeoxycholic Acid Leadiant (chenodeoxycholic acid)

At its meeting on 9 December 2024, the Transparency Council adopted position No. 144/2024 on the appropriateness of issuing approvals for the reimbursement of the medicinal product Chenodeoxycholic Acid Leadiant
(chenodeoxycholic acid) for the indication: cerebral yellowing disease

Publication of the position >>